Findings

What do systematic reviews say?

63 questions · 66 findings · 28 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 13.6%GRADE not reported 0 · 0%Very low 12 · 18.2%Low 17 · 25.8%Moderate 16 · 24.2%High 12 · 18.2%

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Overall survival: Median length of · women with advanced EOC after primary IDS

It is very uncertain whether small‐volume residual disease (SVRD) (< 1 cm) changes overall survival: Median length of compared with NMRD (very low certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 2.09 [1.2, 3.6]
1 study · 310 participants
Very low

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Overall survival: Median length of · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 2.23 [1.49, 3.34]
1 study · 343 participants
Very low

Boost vs no boost

Overall survival: mortality at 5 years · breast‐conserving radiotherapy for breast cancer

Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).

1 finding from 1 review

Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
HR 1.04 [0.94, 1.14]
2 studies · 6342 participants
Moderate